Bifidobacterium-mediated high-intensity focused ultrasound for solid tumor therapy: comparison of two nanoparticle delivery methods

References

• Brown JM. Tumor hypoxia in cancer therapy. Meth Enzymol. 2007;435:297–321.
   PubMed Web of Science ®Google Scholar
• Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 2012;49:24–40. 
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429–441.
   PubMed Web of Science ®Google Scholar
• Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26(2):319–331.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447.
   PubMed Web of Science ®Google Scholar
• Lefevre CT, Bernadac A, Yu-Zhang K, et al. Isolation and characterization of a magnetotactic bacterial culture from the Mediterranean Sea. Environ Microbiol. 2009;11(7):1646–1657.
   PubMed Web of Science ®Google Scholar
• Park SJ, Park SH, Cho S, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.
   PubMed Web of Science ®Google Scholar
• Taniguchi S, Fujimori M, Sasaki T, et al. Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci. 2010;101(9):1925–1932.
   PubMed Web of Science ®Google Scholar
• Zhou H, He Z, Wang C, et al. Intravenous administration is an effective and safe route for cancer gene therapy using the Bifdobacterium mediated recombinant HSV-1 thymidine kinase and ganciclovir. IJMS. 2016;17(6):891.
   Web of Science ®Google Scholar
• Gao X, Zou WJ, Jiang BL, et al. Experimental study of retention on the combination of Bifidobacterium with High-Intensity Focused Ultrasound (HIFU) synergistic substance in tumor tissues. Sci Rep. 2019;9(1):6423.
   PubMed Web of Science ®Google Scholar
• Hwang JH, Crum LA. Crum current status of clinical high-intensity focused ultrasound. Conf Proc IEEE Eng Med Biol Soc. 2009;2009):130–133.
   PubMedGoogle Scholar
• Hsiao YH, Kuo SJ, Tsai HD, et al. Clinical application of High-intensity focused ultrasound in cancer therapy. J Cancer. 2016;7(3):225–231.
   PubMed Web of Science ®Google Scholar
• Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005;5(4):321–327.
   PubMed Web of Science ®Google Scholar
• Umemura S, Kawabata K, Sasaki K. In vivo acceleration of ultrasonic tissue heating by microbubble agent. IEEE Trans Ultrason Ferroelectr Freq Control. 2005;52(10):1690–1698. 
   PubMed Web of Science ®Google Scholar
• Zhou X, Wen L, He G, et al. SonoVue-enhanced high intensity focused ultrasound ablation on rabbit VX2 liver tumors. Ultrasound Med Biol. 2009;8:220–220.
   Google Scholar
• Luo W, Zhou X, Ren X, et al. Enhancing effects of SonoVue, a microbubble sonographic contrast agent, on high intensity focused ultrasound ablation in rabbit livers in vivo. Ultrasound Med. 2007;26(4):469–476.
   PubMed Web of Science ®Google Scholar
• Li Q, Du J, Yu M, et al. Transmission electron microscopy of VX2 liver tumors after high-intensity focused ultrasound ablation enhanced with SonoVue. Adv Ther. 2009;26(1):117–125.
   PubMed Web of Science ®Google Scholar
• Romoren K, Fjeld XT, Poleo AB, et al. Transfection efficiency and cytotoxicity of cationic liposomes in primary cultures of rainbow trout(Oncorhynchus mykiss) gill cells. Biochim Biophys Acta. 2005;1717(1):50–57.
   PubMed Web of Science ®Google Scholar
• Soenen SJ, De Cuyper M. How to assess cytotoxicity of (iron oxide-based) nanoparticles: a technical note using cationic magnetoliposomes. Contrast Media Mol Imaging. 2011;6(3):153–164.
   PubMed Web of Science ®Google Scholar
• Ektate K, Munteanu MC, Ashar H, et al. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci Rep. 2018;8(1): 13062.
   Web of Science ®Google Scholar
• Luo Y, Xu D, Gao X, et al. Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy. Biochem Biophys Res Commun. 2019;514(4):1147–1153.
   PubMed Web of Science ®Google Scholar
• Luo CH, Huang CT, Su CT, et al. Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 2016;16(6):3493–3499.
   PubMed Web of Science ®Google Scholar
• Wang L, Vuletic I, Deng D, et al. Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo. Gene Ther. 2017;24(11):699–705.
   PubMed Web of Science ®Google Scholar
• Zhang B, Jiang T, Tuo YY, et al. Captopril improves tumor nanomedicine delivery by increasing tumor blood perfusion and enlarging endothelial gaps in tumor blood vessels. Cancer Lett. 2017;410:12–19.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631–651.
   PubMed Web of Science ®Google Scholar
• Rapoport NY, Efros AL, Christensen DA, et al. Microbubble generation in phase-shift nanoemulsions used as anticancer drug carriers. Bubble Sci Eng Technol. 2009;1(1–2):31–39.
   PubMedGoogle Scholar
• Mokrozub VV, Lazarenko LM, Babenko LP, et al. Effect of probiotic strains of lacto- and bifdobacteria on the activity of macrophages and other parameters of immunity in cases of staphylococcosis. Mikrobiol Z. 2012;74:90–98.
   PubMedGoogle Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151.
   PubMed Web of Science ®Google Scholar
• Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3(3):319–328.
   PubMed Web of Science ®Google Scholar